High Quality
Open the downloaded document, and select print from the file menu (PDF reader required).
Company Background
IMULAN BioTherapeutics, LLC
www.IMULAN.com480.248.2176
IMULAN BioTherapeutics, LLC (IMULAN) wasformed in 2004 by veterinarians and scientiststo advance immune based therapies forveterinary medicine. In 2005, IMULAN securedthe veteirnary rights to the ImSAIDs, a newclass of patented amino acid complexes.IMULAN remains a company dedicated toproducing unique products by followingtwo general principles:
.
develop clinically relevant and meaningful products, and
.
focus on diseases that are complex and in need of options
Technologies in Development
TCR Peptides
: a new, patented immunemodulator being developed for atopicdermatitis and feline stomatitis. The TCRplatform is also being considered for infectiousdiseases in companion animals and livestock.
Atopy Biomarker
: scientists at IMULANhave identied a serum biomarker that issignicantly higher in atopic dogs. Thisbiomarker is undergoing further evaluationto determine its application in veterinarydermatology.
LeukoSTAT
ImSAIDs® Enabled Product
I
mmune
S
elective
A
nti-
I
nammatory
D
erivatives
All Inammation isRegulated by Leukocytes
TM
ImSAIDs and LeukoSTAT are trademarkesof IMULAN BioTherapeutics, LLC2010 Copyright of IMULAN BioTherapeutics, LLCAll rights reserved
LeukoSTAT comes in 30 and 120count bottles in a highly palatablechewable formula.
Add a Comment